Chronic Obstructive Pulmonary Disease
Conditions
Keywords
COPD
Brief summary
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 compared to placebo and Formoterol Fumarate (Foradil Aerolizer) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Interventions
DRUGInhaled PT005
single dose, inhaled
DRUGInhaled placebo
single dose, inhaled
single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
Sponsors
Pearl Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent * 40 - 80 years of age * Fluency in written and spoken English * Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods * Current/former smokers with at least a 10 pack-year history of cigarette smoking * A measured post-salbutamol FEV1/FVC ratio of \< or = 0.70 * A measured post-salbutamol FEV1 \> or = 40 and \< or = 80% of predicted normal values * Demonstrated reversibility to a short acting beta agonist by either \>12% and \>150 ml improvement in baseline FEV1, 30 minutes following administration of 4 puffs of salbutamol MDI or an absolute improvement of \>200 ml in baseline FEV1, 30 minutes following administration of 4 puffs of salbutamol MDI. * Competent at using the inhalation device
Exclusion criteria
* Women who are pregnant or lactating * Primary diagnosis of asthma * Alpha-1 antitrypsin deficiency as the cause of COPD * Active pulmonary diseases * Prior lung volume reduction surgery * Abnormal chest X-ray (or CT scan) not due to the presence of COPD * Hospitalized due to poorly controlled COPD within 24 weeks of Screening * Poorly controlled COPD in prior 6-weeks, defined as the occurrence of acute worsening of COPD requiring corticosteroids or antibiotics or acute worsening of COPD requiring treatment prescribed by a physician * Clinically significant medical conditions * Lower respiratory tract infection requiring antibiotics in past 6 weeks * Clinically significant abnormal ECG * Clinically significant uncontrolled hypertension * Positive Hepatitis B surface antigen or Hepatitis C antibody * Cancer that has not been in complete remission for at least 5 years * History of hypersensitivity to any beta2-agonists or any study drug component * History of severe milk protein allergy * Known or suspected history of alcohol or drug abuse * Medically unable to withhold short acting bronchodilators for 8-hours * Use of the medications below in specified time interval prior to Screening: 12-weeks: depot corticosteroids, intra-articular corticosteroids; 4 weeks: ICS \>1000 μg/day of fluticasone propionate or equivalent, non-potassium sparing diuretics, P-glycoprotein inhibitors, CYP3A4 inhibitors; 1 week: tiotropium; 48 hours: oral beta agonists, long acting beta agonists, theophylline, zariflukast, montelukast, zileuton; 8 hours: ipratropium or ipratropium/salbutamol combination product, inhaled short acting beta agonists, xanthine containing foods * Use of the following medications is prohibited: tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, beta-adrenergic antagonists, anticonvulsants (barbiturates,hydantoins, and carbamazepine and phenothiazines * Receiving long-term-oxygen or nocturnal oxygen therapy for \>12 hours a day * Diagnosis of sleep apnea that is uncontrolled * Participation in acute phase of pulmonary rehabilitation in prior 4 weeks or will enter acute phase of pulmonary rehabilitation program during study * Unable to comply with study procedures * Affiliated with Investigator site * Questionable validity of consent * A positive drug of abuse test at Screening lives prior to Screening, whichever is longer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in forced expiratory volume in one second (FEV1) area under the curve from 0 to 12 hours [AUC(0-12)] from test day baseline across the three doses of inhaled PT005 compared with placebo. | Serial FEV1 measured over 12 hours |
Secondary
| Measure | Time frame |
|---|---|
| Peak FEV1 | Serial FEV1 measured over 12 hours |
| Trough FEV1 | Serial FEV1 measured over 12 hours |
| Time to onset of action (>10% improvement in FEV1 from baseline) | Serial FEV1 measured over 12 hours |
| Peak expiratory flow rate (PEFR) | Serial PEFR measured over 12 hours |
| Forced vital capacity (FVC) | Serial FVC measured over 12 hours |
| Peak inspiratory capacity (IC) | Serial IC measured over 12 hours |
Countries
Australia, New Zealand
Outcome results
None listed